Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | PPARD | Q03181 | 2/20 | 0.37 |
| ▸ | PPARA | Q07869 | 2/20 | 0.37 |
| ▸ | BMP1 | P13497 | 2/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | CETP | P11597 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20182405 | 0.89 | LTB4R2 (0.42) | LTB4R2RXRABMP1MAOBCETP | |
| SCHEMBL20570505 | 0.80 | LTB4R2 (0.42) | LTB4R2RXRARXRBRXRGUSP2 | |
| SCHEMBL25802749 | 0.76 | TSPO (0.46) | PPARGPPARA | |
| SCHEMBL20137115 | 0.72 | LTB4R2 (0.44) | LTB4R2PPARGBMP1MAOBCETP | |
| SCHEMBL28880216 | 0.71 | BCL2A1 (0.41) | USP2TSHRPPARGPPARDPPARA | |
| SCHEMBL7793185 | 0.70 | RAB9A (0.47) | RXRARXRBRXRGBMP1MAOB | |
| SCHEMBL31057445 | 0.70 | TSPO (0.52) | — | |
| SCHEMBL20137411 | 0.70 | LTB4R2 (0.40) | LTB4R2RXRABMP1 | |
| SCHEMBL9172532 | 0.69 | MEP1B (0.58) | USP2TSHRBMP1LTB4RFFAR1 | |
| SCHEMBL31057599 | 0.69 | BCL2A1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11059822-B2 | MAGL inhibitors | H. LUNDBECK A/S (DK) | 2021-07-13 | — | — | US | disclosed |
| US-20200291023-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059822-B2 | MAGL inhibitors | MAG, MAGI3, MGLL | LTB4R2 2100/4885RXRA 2778/4885RXRB 2555/4885 |
| US-20200291023-A1 | MAGL INHIBITORS | MAG, MAGI3, MGLL | LTB4R2 2100/4885RXRA 2778/4885RXRB 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.